TSHA | Taysha Gene Therapies, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	1.7500 - 1.8400
52 Week Range	1.1900 - 4.32
Beta	1.44
Implied Volatility	661.10%
IV Rank	20.37%
Day's Volume	221,976
Average Volume	4,376,591
Shares Outstanding	204,943,000
Market Cap	372,996,260
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-09-24

Valuation
Profitability
Growth
Health
P/E Ratio	2.89
Forward P/E Ratio	N/A
EPS	0.63
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	52
Country	USA
Website	TSHA

Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN1 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 foe the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.

TSHA's peers: BMEA, STOK, AKRO, FIXX, GOSS, XFOR, INZY, TERN, DAWN, HOOK, GLUE, CABA, LRMR, ALEC, STTK, CCCC, ELYM, PRLD

*Chart delayed

Analyzing fundamentals for TSHA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see TSHA Fundamentals page.

Watching at TSHA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on TSHA Technicals page.